EA
MYGN icon

Emerald Acquisition’s Myriad Genetics MYGN Stock Holding History

Emerald Acquisition’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$26.6M Buy
1,291,766
+400,106
+45% +$10.1M 0.05% 425
2016
Q2 		$27.3M Buy
+891,660
New +$31M 0.05% 466

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Emerald Acquisition's MYGN Position: Q3 2016 in Review

Emerald Acquisition increased its Myriad Genetics (MYGN) stake by 45% in Q3 2016, buying an estimated $10.1M and bringing the position to 1,291,766 shares worth $26.6M. The position accounts for 0.05% of the portfolio, ranked #425.

Emerald Acquisition first reported a position in MYGN in Q2 2016 and has held it in 2 quarters since. The position peaked at $27.3M in Q2 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

  • Emerald Acquisition held 1,291,766 shares of Myriad Genetics worth $26.6M as of Q3 2016.
  • Emerald Acquisition bought 400,106 Myriad Genetics shares in Q3 2016, an estimated $10.1M.
  • Myriad Genetics made up 0.05% of Emerald Acquisition's portfolio in Q3 2016, its #425 holding.
  • Emerald Acquisition first reported a position in Myriad Genetics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Myriad Genetics position peaked at $27.3M in Q2 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.